Literature DB >> 28646276

Rhizopus arrhizus Invasive Infection due to Self-Inflicted Scratch Injuries in a Diabetic Patient with Non-ketotic Acidosis.

Luis Buzón Martín1, Miguel Ángel Morán Rodríguez2, Nicole Mercier2, Maria Ortega Lafont2, Eva Ojeda Fernández2, Ana Ruiz de la Parte2, Miguel Estefanía2.   

Abstract

Mucormycosis is a rare infection caused by members included in the subphylum Mucoromycotina. Characterized by the histopathological hallmark of angioinvasion, these infections affect most often patients with certain underlying conditions carrying immunosuppression (haematological neoplasias, diabetic ketoacidosis and other forms of acidosis, and iron overload) or immunocompetent patients with traumatic mucocutaneous barriers breakdown and direct inoculation of the mould. A case is presented in which a rare underlying condition (non-ketotic acidosis) and a rare cause of cutaneous injuries collide. Prognosis, treatment options and management decisions are described thoroughly.

Entities:  

Keywords:  Mucormycosis; Non-ketotic acidosis; Rhizopus

Mesh:

Substances:

Year:  2017        PMID: 28646276     DOI: 10.1007/s11046-017-0158-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  30 in total

1.  Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Authors:  A Espinel-Ingroff; A Chakrabarti; A Chowdhary; S Cordoba; E Dannaoui; P Dufresne; A Fothergill; M Ghannoum; G M Gonzalez; J Guarro; S Kidd; C Lass-Flörl; J F Meis; T Pelaez; A M Tortorano; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 2.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 3.  Healthcare-associated mucormycosis.

Authors:  Blandine Rammaert; Fanny Lanternier; Jean-Ralph Zahar; Eric Dannaoui; Marie-Elisabeth Bougnoux; Marc Lecuit; Olivier Lortholary
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

4.  Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka.

Authors:  David Andresen; Annabelle Donaldson; Lennart Choo; Adrian Knox; Michael Klaassen; Caesar Ursic; Leon Vonthethoff; Steven Krilis; Pamela Konecny
Journal:  Lancet       Date:  2005 Mar 5-11       Impact factor: 79.321

5.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 6.  Global epidemiology of cutaneous zygomycosis.

Authors:  Anna Skiada; Dimitris Rigopoulos; George Larios; George Petrikkos; Andreas Katsambas
Journal:  Clin Dermatol       Date:  2012 Nov-Dec       Impact factor: 3.541

Review 7.  Gangrenous cutaneous mucormycosis caused by Rhizopus oryzae: a case report and review of primary cutaneous mucormycosis in China over Past 20 years.

Authors:  HouMin Li; Sonia Kay Hwang; Cheng Zhou; Juan Du; JianZhong Zhang
Journal:  Mycopathologia       Date:  2013-04-25       Impact factor: 2.574

Review 8.  Cutaneous mucormycosis: report of five cases and review of the literature.

Authors:  M E Arnáiz-García; D Alonso-Peña; M del Carmen González-Vela; J D García-Palomo; J R Sanz-Giménez-Rico; A M Arnáiz-García
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-08-05       Impact factor: 2.740

Review 9.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

Authors:  O A Cornely; S Arikan-Akdagli; E Dannaoui; A H Groll; K Lagrou; A Chakrabarti; F Lanternier; L Pagano; A Skiada; M Akova; M C Arendrup; T Boekhout; A Chowdhary; M Cuenca-Estrella; T Freiberger; J Guinea; J Guarro; S de Hoog; W Hope; E Johnson; S Kathuria; M Lackner; C Lass-Flörl; O Lortholary; J F Meis; J Meletiadis; P Muñoz; M Richardson; E Roilides; A M Tortorano; A J Ullmann; A van Diepeningen; P Verweij; G Petrikkos
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

View more
  1 in total

1.  Development of a Monoclonal Antibody and a Serodiagnostic Lateral-Flow Device Specific to Rhizopus arrhizus (Syn. R. oryzae), the Principal Global Agent of Mucormycosis in Humans.

Authors:  Genna E Davies; Christopher R Thornton
Journal:  J Fungi (Basel)       Date:  2022-07-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.